Monthly Archives: August 2024

The Delaware Court of Chancery Undertakes Exacting Calculations of Equitable Damages

Alex J. Kaplan is a Partner and Kedrick Glinski is a Summer Associate at Sidley Austin LLP. This post is based on their Sidley memorandum and is part of the Delaware law series; links to other posts in the series are available here.

The Delaware Court of Chancery is of course a court of equity, focusing often on governance and contractual rights. The Court of Chancery also periodically issues damages opinions, and on May 28, 2024, Vice Chancellor Lori Will did just that in Brown v. Matterport, Inc. At issue in Matterport was whether the plaintiff stockholder—following an earlier trial ruling that the defendant corporation had wrongfully (albeit in good faith) prohibited the stockholder from selling his shares—was entitled to damages and, if so, the proper method for computing damages. Vice Chancellor Will held that damages were appropriate based on the facts at issue, and in issuing a damages award of approximately $79 million, the Court undertook a rigorous approach in determining both the appropriate method to compute damages as well as the inputs for that calculation.

READ MORE »

Court Dismisses Most of SEC’s Claims Against SolarWinds

Robert W. Downes and Nicole Friedlander are Partners and Paulena B. Prager is an Associate at Sullivan & Cromwell LLP. This post is based on a Sullivan & Cromwell memorandum by Mr. Downes, Ms. Friedlander, Ms. Prager, and John B. Sarlitto.

Ruling Curtails SEC’s Authority to Bring “Internal Accounting Controls” Charges, and Rejects SEC’s Claims that Company’s Securities Filings Were False and Its Disclosure Controls Failed in Connection with a Cybersecurity Breach

SUMMARY

On July 18, 2024, Judge Paul A. Engelmayer of the United States District Court for the Southern District of New York granted, in large part, a motion by SolarWinds Corporation (“SolarWinds”) and its Chief Information Security Officer (“CISO”) to dismiss the fraud and internal controls charges brought against them by the Securities and Exchange Commission (“SEC”) in the aftermath of a compromise of the company’s software product that was disclosed in December 2020. The court allowed only the subset of claims alleging that the “Security Statement” on the company’s website was materially false to survive.

The case, which has been closely followed, is the first in which the SEC has charged a CISO individually in connection with alleged cybersecurity violations and the first in which it has charged scienter-based securities fraud in connection with a cybersecurity breach. The case also represents a rare instance in which a company has challenged the SEC’s expansive reading of its authority to charge a violation of the “internal accounting controls” provision of the Securities Exchange Act of 1934 (the “Exchange Act”) based on an alleged failure of internal corporate controls—in this case, cybersecurity controls—not limited to financial accounting. The court’s opinion has significant implications for public companies as they assess their cybersecurity risk management, governance and disclosure practices, and, beyond the cybersecurity context, in its finding that the SEC is not authorized to charge internal accounting controls violations that are not specifically tied to financial accounting controls.

READ MORE »

Chancery Finds 26.7% Stockholder Was Not a Controller

Gail Weinstein is a Senior Counsel, Philip Richter is a Partner, and Steven Epstein is a Managing Partner at Fried, Frank, Harris, Shriver & Jacobson LLP. This post is based on a Fried Frank memorandum by Ms. Weinstein, Mr. Richter, Mr. Epstein, Steven Steinman, Maxwell Yim, and Alison McCormick, and is part of the Delaware law series; links to other posts in the series are available here.

In Sciannella v. AstraZeneca (July 2, 2024), the Delaware Court of Chancery, at the pleading stage of litigation, dismissed claims that AstraZeneca UK, the 26.7% owner of Viela Bio, Inc. (the “Company”), and certain Company directors and officers, breached fiduciary duties in connection with the $3 billion arm’s-length sale of the Company to Horizon Therapeutics, Inc. The Plaintiff contended that AstraZeneca controlled the Company, and that, to facilitate securing antitrust clearance for AstraZeneca’s $38 billion acquisition of Alexion Pharmaceuticals, Inc. (the Company’s main competitor), AstraZeneca pushed the Company into a quick sale to Horizon by threatening to terminate its support agreements with the Company.

AstraZeneca, which had created the Company via a spinoff of its business, effectively had certain blocking rights (given the requirement in the Company’s charter of a 75% stockholder vote for certain actions); had designated AstraZeneca executives as directors on the Company’s board (and the Plaintiff alleged that the other directors also were “beholden” to AstraZeneca for various reasons); had appointed former AstraZeneca executives to key management positions (including the CEO); and had total control over the Company’s day-to-day operations through a “web” of support agreements. Also, the Company acknowledged in its public filings that it substantially relied on AstraZeneca and would face operational difficulties if AstraZeneca did not continue to provide support services to the Company.

The court found that (i) AstraZeneca was not a controller, and therefore owed no fiduciary duties to the Company and its stockholders; and (ii) the Company’s disclosure to the stockholders was adequate, and therefore any fiduciary breaches by Company directors and officers were cleansed under Corwin.

READ MORE »

Weekly Roundup: July 26-August 1, 2024


More from:

This roundup contains a collection of the posts published on the Forum during the week of July 26-August 1, 2024

The Potential Impact of the DGCL Market Practice Amendments on Activism Settlements




Clawback Provisions that Go Beyond SEC Requirements are Prevalent Among Large-Cap Companies


Not Even a Raging Bull Market Can Rescue SPACs


Negative Trading in Congress


Delaware Governor Signs Controversial “Market-Practice” Amendments to General Corporation Law


Business Judgment and Valuing Impacts



Director Wins In Claim of Improper Removal – But Still Loses


Multiple-voting shares in Europe – A comparative law and economic analysis


Anti-ESG Proposal Surged in 2024 But Earned Less Support


Nasdaq toughens up suspension and delisting process for SPACs


Litigation Risk and Strategic M&A Valuation


Governance of transformation amid an uncertain business climate


Governance of transformation amid an uncertain business climate

Carey Oven is a National Managing Partner, and Annie Adams and Mauricio Garza are Managing Directors at Deloitte LLP. This post is based on their Deloitte memorandum.

Why it matters

It seems an understatement to characterize the current state of global affairs as “volatile.” If the past few years have shown anything, it’s that boards can be certain of at least one thing: an uncertain governance landscape. Volatility wrought by a pandemic, economic upheavals, and geopolitical conflict—to name just a few challenges of late—have added a suite of new risks for boards to navigate.[1] Finding a way through such turbulent waters isn’t easy. But according to Deloitte’s MarginPLUS 2024 Survey, a growing number of companies are charting a course with the help of transformation initiatives focused on margin improvement.[2]

Regardless of form, transformation initiatives may involve large-scale changes that aim to bolster efficiency, reduce manual processes, and otherwise modernize business operations. Their scale and scope (from individual business units to organizationwide) can be different across industry as can the governance processes. In this article, we highlight three areas of focus for boards when overseeing transformation initiatives.

> External pressures

Governing the (sometimes) turbulent transformation process.

> Targeted transformation

A possible emerging trend of focused initiatives is on the governance horizon.

> Vigilant governance

Proactive board oversight of strategy may help organizations realize transformation goals.

READ MORE »

Litigation Risk and Strategic M&A Valuation

Benjamin Yost is an Associate Professor of Accounting at Boston College Carroll School of Management. This post is based on an article forthcoming in the Journal of Accounting & Economics (JAE) by Professor Yost, Professor Claudia Imperatore, Professor Gabriel Pundrich, and Professor Rodrigo Verdi.

The vast majority of mergers and acquisitions (M&As) in recent decades employ fairness opinions (FOs). FOs are provided by an outside advisor (typically an investment bank), and reflect the advisor’s opinion that the terms of the transaction are “fair” to the shareholders from a financial perspective. Advisors support their opinion that the deal terms are fair using a range of valuation methodologies, the two most common being peer firm comparables and DCF analysis. However, despite the ubiquitous use of FOs in mergers, their role is not well understood. On the one hand, some studies argue that FOs provide new information to market participants and serve as a tool for managers to negotiate over transaction price. On the other hand, it has been conjectured (but not tested) that FOs are used primarily to protect managers and boards from litigation and ensure successful deal completion. In our study, “Litigation risk and strategic M&A valuations”, which is forthcoming in the Journal of Accounting & Economics, we explicitly test this conjecture, with a particular focus on the relation between M&A litigation risk and FO valuations.

READ MORE »

Nasdaq toughens up suspension and delisting process for SPACs

Cydney Posner is Special Counsel at Cooley LLP. This post is based on her Cooley memorandum.

Nasdaq has just filed a proposal, Notice of Filing and Immediate Effectiveness of Proposed Rule Change to Amend Certain Procedures Related to the Suspension and Delisting of Acquisition Companies, designed to address the suspension and delisting process applicable to Acquisition Companies, companies such as SPACs with business plans to complete one or more acquisitions, as described in Rule IM-5101-2. The rule changes would apply to an Acquisition Company that “fails to (i) complete one or more business combinations satisfying the requirements set forth in Listing Rule IM-5101-2(b) (“Business Combination”) within 36 months of the effectiveness of its IPO registration statement; or (ii) meet the requirements for initial listing following the Business Combination.” The proposal would also “limit the Hearings Panels authority to review the Nasdaq Staff’s decision in these instances to a review for factual error only.” Nasdaq also proposes to clarify Listing Rule 5810(c)(1) (with no substantive change) to improve transparency and readability.  The rule changes will be operative for Staff Delisting Determination letters issued on or after October 7, 2024.

READ MORE »

Page 6 of 6
1 2 3 4 5 6